141 related articles for article (PubMed ID: 31685739)
1. [QOL Assessment in Chronic Hepatitis C Patients Receiving Ledipasvir/ Sofosbuvir or Simeprevir/Peginterferon/Ribavirin in Clinical Practice].
Aimono Y; Kohyama N; Kamoshida T; Yamamoto T; Kogo M
Yakugaku Zasshi; 2019; 139(11):1427-1434. PubMed ID: 31685739
[TBL] [Abstract][Full Text] [Related]
2. Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.
Yin S; Barker L; White JZ; Jiles RB
J Manag Care Spec Pharm; 2019 Feb; 25(2):195-210. PubMed ID: 30698086
[TBL] [Abstract][Full Text] [Related]
3. Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.
Shin HP; Burman B; Kozarek RA; Zeigler A; Wang C; Lee H; Zehr T; Edwards AM; Siddique A
Gut Liver; 2017 Sep; 11(5):711-720. PubMed ID: 28651301
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
Modi AA; Nazario HE; Gonzales GR; Gonzalez SA
Aliment Pharmacol Ther; 2018 May; 47(10):1409-1415. PubMed ID: 29569736
[TBL] [Abstract][Full Text] [Related]
5. Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir.
Younossi ZM; Stepanova M; Omata M; Mizokami M; Walters M; Hunt S
Medicine (Baltimore); 2016 Aug; 95(33):e4243. PubMed ID: 27537553
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Tao T; Jiang X; Chen Y; Song Y
Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
Sirinawasatien A; Techasirioangkun T
PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
[TBL] [Abstract][Full Text] [Related]
9. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
Younossi ZM; Stepanova M; Pol S; Bronowicki JP; Carrieri MP; Bourlière M
Liver Int; 2016 Jan; 36(1):42-8. PubMed ID: 26059860
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
Younossi ZM; Stepanova M; Henry L; Han KH; Ahn SH; Lim YS; Chuang WL; Kao JH; Nguyen KV; Lai CL; Chan HL; Wei L
J Viral Hepat; 2018 Dec; 25(12):1429-1437. PubMed ID: 29974665
[TBL] [Abstract][Full Text] [Related]
11. Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis.
Essa M; Sabry A; Abdelsameea E; Tharwa ES; Salama M
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):53-58. PubMed ID: 30247174
[TBL] [Abstract][Full Text] [Related]
12. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.
Saab S; Park SH; Mizokami M; Omata M; Mangia A; Eggleton E; Zhu Y; Knox SJ; Pang P; Subramanian M; Kowdley K; Afdhal NH
Hepatology; 2016 Apr; 63(4):1112-9. PubMed ID: 26704693
[TBL] [Abstract][Full Text] [Related]
15. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N
Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144
[TBL] [Abstract][Full Text] [Related]
16. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
[TBL] [Abstract][Full Text] [Related]
17. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).
Younossi ZM; Stepanova M; Henry L; Gane E; Jacobson IM; Lawitz E; Nelson D; Nader F; Hunt S
J Hepatol; 2014 Apr; 60(4):741-7. PubMed ID: 24333184
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir.
Younossi ZM; Stepanova M; Chan HLY; Lee MH; Yu ML; Dan YY; Choi MS; Henry L
Medicine (Baltimore); 2016 Mar; 95(9):e2702. PubMed ID: 26945356
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M
Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890
[TBL] [Abstract][Full Text] [Related]
20. Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials.
Younossi Z; Stepanova M; Omata M; Mizokami M; Walters M; Hunt S
Health Qual Life Outcomes; 2017 Jan; 15(1):25. PubMed ID: 28143559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
